SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Net Income towards Common Stockholders for 9 consecutive years, with -$6.7 million as the latest value for Q4 2024.
- On a quarterly basis, Net Income towards Common Stockholders rose 17.2% to -$6.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$30.9 million, a 18.16% increase, with the full-year FY2024 number at -$30.9 million, up 17.31% from a year prior.
- Net Income towards Common Stockholders was -$6.7 million for Q4 2024 at SELLAS Life Sciences, up from -$7.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.4 million in Q1 2021 to a low of -$16.7 million in Q1 2022.
- A 5-year average of -$7.4 million and a median of -$7.1 million in 2022 define the central range for Net Income towards Common Stockholders.
- Peak YoY movement for Net Income towards Common Stockholders: surged 61.0% in 2020, then crashed 596.42% in 2022.
- SELLAS Life Sciences' Net Income towards Common Stockholders stood at -$3.7 million in 2020, then tumbled by 77.56% to -$6.6 million in 2021, then tumbled by 43.16% to -$9.4 million in 2022, then grew by 13.87% to -$8.1 million in 2023, then increased by 17.2% to -$6.7 million in 2024.
- Per Business Quant, the three most recent readings for SLS's Net Income towards Common Stockholders are -$6.7 million (Q4 2024), -$7.1 million (Q3 2024), and -$7.5 million (Q2 2024).